Teva Agilect “Approvable” For Parkinson’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is pursuing an indication for rasagiline as monotherapy in early Parkinson’s disease and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease.